Early treatment study
et al., medRxiv, doi:10.1101/2020.08.20.20178772 (Preprint)
Hydroxych loroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study
Retrospective 1,274 outpatients, 47% reduction in hospitalization with HC
Q with propensity matching, HC
Q OR 0.53 [0.29-0.95]. Sensitivity analyses revealed similar associations.
Adverse events were not increased (2% QTc prolongation events, 0% arrhythmias).
hospitalization, ↓45.9%, p=0.03
(odds ratio converted to relative risk)
Please send us corrections, updates, or comments.